MetaCap

Innoviva (INVA) vs LB Pharmaceuticals (LBRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

LB Pharmaceuticals (LBRX) has outperformed Innoviva (INVA) over the past year, gaining 153.4% versus a loss of 12.2%. Innoviva is the larger company by market cap ($1.31 billion vs $1.26 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INVA-12.17%LBRX+153.42%
+235%+105%-24%
Nov 21, 20251 yearNov 20, 2026
INVA-4.96%LBRX+131.25%
+204%+91%-21%
Sep 8, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INVA versus LBRX key metrics
MetricINVALBRX
Share price$18.41$38.85
Market cap$1.31B$1.26B
1-day change0.00%-2.97%
YTD return-7.90%+74.53%
1-year return-12.17%+153.42%
5-year return+8.81%—
P/E ratio (TTM)7.83—
Forward P/E8.33—
EPS (TTM)$2.35$-1.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$411.33M—
Revenue growth (YoY)+14.67%—
Net income (latest FY)$271.17M$-25.20M
Gross margin74.80%—
Operating margin39.81%—
Net margin65.92%—
52-week high$25.15$50.16
52-week low$18.19$15.55
Distance from 52-week high-26.80%-22.55%
Analyst consensusbuystrong_buy
Avg. price target upside+89.03%+49.29%
Average volume865.66K373.16K
Shares outstanding71.08M32.36M
Employees15962
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LBRX has outperformed INVA by 165.6 percentage points over the past year.

About Innoviva

INVA stock →

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees

About LB Pharmaceuticals

LBRX stock →

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.

Health Care · Biotechnology: Pharmaceutical Preparations · 62 employees

INVA vs LBRX FAQ

Which is bigger, Innoviva or LB Pharmaceuticals?

Innoviva (INVA) is larger, with a market capitalization of $1.31B compared with $1.26B for LB Pharmaceuticals (LBRX).

Which stock has performed better over the past year, INVA or LBRX?

LBRX returned +153.42% over the past 12 months, compared with -12.17% for INVA (price return, excluding dividends). Past performance does not predict future results.

Are Innoviva and LB Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons